| 摘要 |
Disclosed is the use of ranolazine for the manufacture of a sustained release pharmaceutical dosage form for treating a human patient suffering from a cardiovascular disease selected from arrhythmias, variant and exercise-induced angina, and myocardial infarction, said dosage form including at least 50% by weight ranolazine in no more than two tablets per dose to the human patient to maintain ranolazine plasma levels in the human patient at a minimum of 850 ng base/mL for at least 24 hours, said dose to be administered at a frequency selected from once, twice and three times over 24 hours.
|
